Cannabis Use Among Cancer Patients During Active Treatment: Findings From a Study at an NCI ‐Designated Cancer Center
Cancer Medicine · 2024
DOI: 10.1002/cam4.70384 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Amrit Baral und 6 weiteren Autor:innen. Beteiligte Einrichtung: Miller School of Medicine, University of Miami, Miami, Florida, USA. Hauptthemen laut MEDLINE: Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIMHD NIH HHS, National Institute on Minority Health and Health Disparities.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Objective
This study aims to describe patterns, sources, and reasons for cannabis use among cancer patients during active treatment (+CDTX) compared to no‐use during active treatment (−CDTX).
Methods
Data are from 385 surveys collected via REDCap during phase I of an ongoing study among adult cancer patients seen at an NCI‐designated comprehensive cancer center within the last 5 years of treatment. A harmonized survey was created with 11 other NCI centers to assess cannabis use patterns, sources, and reasons for use. Sociodemographics and cancer details were also collected via self‐report. Descriptive statistics were calculated and stratified by +/−CDTX. Chi‐squared tests were conducted to compare proportions between groups.
Results
Among the sample [49.5 years (SD 15.9); 53.0% male; and 41.6% Hispanic/Latino], 41.0% + CDTX and 59.0% −CDTX. A majority (71.8%) of +CDTX initiated use before diagnosis versus 44.1% in −CDTX ( p < 0.0001); patients diagnosed with stage 4 cancer had a statistically significant higher prevalence of +CDTX (60.0%; p = 0.003); 53.3% in radiation reported +CDTX compared to 42.8% in chemotherapy, and 36.4% in immunotherapy. Dispensaries and local dealers were the top sources of cannabis in both groups. Among +CDTX, 44.3% consumed cannabis at least once a day DTX, dominant cannabinoids used were CBD (35.2%), Delta‐8‐THC (18.3%), and CBD + THC ratio (14.1%); 12.7% were unsure what they consumed. Joints were the most common inhalation method (61.5%), and store‐bought candy was the most common edible (39.2%). Depression/mood, pain, and enjoyment were the top three reasons for +CDTX compared to enjoyment, depression/mood, and nausea/upset stomach in −CDTX ( p = 0.02).
Conclusions
Patterns, sources, and reasons for cannabis use varied between +CDTX and ‐CDTX. Future studies should examine the impacts of cannabis and specific cannabinoids on cancer treatment, drug interactions, survival outcomes, and quality of life.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Miller School of Medicine, University of Miami, Miami, Florida, USA.
- Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, USA.
- School of Nursing and Health Studies, University of Miami, Coral Gables, Florida, USA.
ORCID-Profile: Amrit Baral, Ranya Marrakchi El Fellah
Förderung
- NCI NIH HHS
- NIMHD NIH HHS
- National Institute on Minority Health and Health Disparities
- National Cancer Institute
Zitieren
APA
Baral, A., Diggs, B. A., Marrakchi El Fellah, R., McCarley, C., Penedo, F., Martinez, C., & Vidot, D. C. (2024). Cannabis Use Among Cancer Patients During Active Treatment: Findings From a Study at an NCI ‐Designated Cancer Center. Cancer Medicine. https://doi.org/10.1002/cam4.70384
Vancouver
Baral A, Diggs BA, Marrakchi El Fellah R, McCarley C, Penedo F, Martinez C, et al. Cannabis Use Among Cancer Patients During Active Treatment: Findings From a Study at an NCI ‐Designated Cancer Center. Cancer Medicine. 2024. doi:10.1002/cam4.70384
BibTeX
@article{Baral2024,
author = {Baral, Amrit and Diggs, Bria-Necole A and Marrakchi El Fellah, Ranya and McCarley, Connor and Penedo, Frank and Martinez, Claudia and Vidot, Denise C},
title = {Cannabis Use Among Cancer Patients During Active Treatment: Findings From a Study at an NCI ‐Designated Cancer Center},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.70384}
}
EUVIMED